FOR IMMEDIATE RELEASE

Media Contact:
Dan Budwick, Pure Communications
dan@purecommunicationsinc.com
973-271-6085

SAGE’s Novel Approach to Treatment of CNS Disorders to be Highlighted at Leading Industry and Scientific Conferences

Cambridge, Mass. – November 18, 2013 – SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced the company’s pipeline programs and science behind its novel therapeutic product engine will be highlighted at three key upcoming conferences.

• **Therapeutic Area Partnerships Conference:** SAGE-547, a proprietary investigational treatment for status epilepticus, has been selected by Elsevier Business Intelligence as one of the Top 10 Neuroscience Projects to Watch. Kiran Reddy, M.D., chief business officer of SAGE, will provide a program overview and clinical update on SAGE-547 during his presentation at 1:30 pm tomorrow at the Hyatt Regency in Boston.

• **American Epilepsy Society (AES) Annual Meeting:** Data from a late-breaking abstract will be presented in a poster titled “Generation of synthetic neuroactive steroids with potent positive modulatory activity at GABA$_A$ synaptic and extra-synaptic receptors for the treatment of epilepsy” from 12 to 2 pm on Monday, Dec. 9 at the AES annual meeting in Washington, D.C., at the Walter E. Washington Convention Center. This work highlights SAGE’s productive chemistry platform and its novel approach of targeting GABA$_A$ receptors.

• **American College of Neuropsychopharmacology Annual Meeting:** Steven Paul, M.D., founder of SAGE, member of the company’s board of directors and chair of its scientific advisory board, will co-chair a panel session titled “Neuroactive Steroids and Oxysterols as Endogenous Modulators of GABA and Glutamate Receptors: Basic Mechanisms and Therapeutic Implications.” This panel will feature a series of presentations highlighting allosteric modulation of GABA$_A$ and NMDA receptors, a novel therapeutic approach to potentially treat a broad range of neuropsychiatric disorders and the scientific foundation of SAGE’s product platform. The panel will take place from 8:30 to 11 am on Tuesday, Dec. 10 at the Westin Diplomat in Hollywood, Florida.

“We are pleased to see data demonstrating the great promise of our near-term clinical programs and therapeutic platform for the treatment of epilepsy and other debilitating chronic CNS disorders featured at these meetings,” said Jeffery Jonas, chief executive officer of SAGE. “CNS diseases continue to represent an area of huge unmet need, and SAGE’s unique approach of fine tuning brain activity could prove more effective for a wide range of CNS disorders without the side effects that have historically plagued CNS drugs. We look forward to continuing to advance these programs and, ultimately, delivering better therapies to patients.”
About SAGE Therapeutics
SAGE Therapeutics is a neuroscience company developing therapies to treat CNS specialty and orphan diseases. The company has identified several product opportunities with clear and accelerated paths to regulatory approval. SAGE’s initial pipeline includes programs in status epilepticus, anesthesia, Fragile X Syndrome and traumatic brain injury, where CNS drugs poorly address the areas of most urgent patient need and are often accompanied by considerable side effects. The company’s Positive and Negative Allosteric Modulator (PANAM) platform has generated multiple new chemical entities supported by promising preclinical data with the potential to lead to products with utility for multiple indications over the next several years. SAGE Therapeutics is a private company launched in 2011 by a proven team of R&D leaders, renowned CNS experts and funded by Third Rock Ventures and Arch Ventures. For more information, please visit www.sagerx.com.

###